Antifungal stewardship (AFS) programmes are needed in tertiary-care hospitals. Our aim is to describe a bedside non-restrictive AFS programme, and to evaluate its economic impact. During the first year of the AFS a bundle of non-interventional measures were implemented. During the second year an infectious diseases specialist visited 453 patients receiving candins, liposomal amphotericin B, voriconazole or posaconazole. Monthly costs were studied with an interrupted time series (ITS) analysis. The main prescribing departments were haematology (35%), medical departments (23%), and intensive care units (20%). Reasons to start antifungal therapy were: targeted therapy (36%), prophylaxis (32%), empirical therapy (20%) and pre-emptive therapy (12%). At the initial visit, diagnostic advice was provided in 40% of cases. The most common therapeutic recommendations were to de-escalate the antifungal drug (17%) or to suspend it (7%). Annual total antifungal expenditure was reduced from US$3.8 million to US$2.9 million over the first 2 years, generating net savings of US$407,663 and US$824,458 per year after considering the cost of additional staff required. The ITS analyses showed a significant economic impact after the first 12 months of the intervention (p 0.042 at month 13), which was enhanced in the following 24 months (p 0.006 at month 35). The number of defined daily doses decreased from 66.4 to 54.8 per 1000 patient-days.
Introduction
The high mortality and diagnostic challenge of invasive fungal infections (IFIs) have encouraged the use of broad-spectrum and costly antifungal agents. These drugs are frequently prescribed as pre-emptive or empirical treatments, sometimes with questionable indications [1] .
Antimicrobial stewardship programmes are considered an essential part of policies to enhance safety and are endorsed by scientific societies [2] . Although significant success has been demonstrated with antibacterial stewardship interventions, experience with antifungal drugs is scarce. Some programmes include formulary restriction and preauthorization requirements [3] [4] [5] or did not include all available antifungal agents [6] [7] [8] . Nowadays, when competition for resources is huge and proof of return on investment is a requisite, the costeffectiveness and safety of antifungal stewardship programmes (AFSPs) need to be demonstrated.
We describe the design, implementation and assessment of a non-compulsory, multidisciplinary AFSP performed over a 2year period in a tertiary-care hospital. Our objectives were to describe the implementation of the AFSP and to evaluate its impact on costs. The most common causes of misuse of antifungal drugs in a general hospital were also analysed.
Materials and methods

Study design
This was a quasi-experimental study with a time series design. The primary outcome of the study was the reduction in antifungal expenditure. Secondary outcomes included assessment of the percentage of appropriate antifungal prescriptions, candidaemia incidence, candidaemia mortality rate, and percentage of fluconazole resistance. ORION guidelines [9] and TIDieR checklist [10] were fulfilled.
Background
Our AFSP was conducted at Gregorio Marañón Hospital, a general tertiary-care teaching hospital with 1550 beds serving a population of 750 000 inhabitants in Madrid, Spain, with approximately 65 000 admissions per year. The hospital is a referral centre for solid organ transplantation, heart surgery, oncology (38 beds), haematology (13 beds), bone marrow transplantation (eight beds), and HIV/AIDS care. It has five intensive care units (ICU: three for adults and two for paediatric patients (approximately 96 intensive care beds)). Adult and paediatric infectious diseases consultation services are readily available (210-275 formal consultations per month).
Available diagnostic tools include fungal cultures, sensitivity, serological (galactomannan, Candida albicans germ tube antibodies (CAGTA), Platelia™ Candida and cryptococcal antigen) and molecular tests (Aspergillus PCR). Histopathology examination, computed tomography scans and magnetic resonance imaging are also available.
Approximately 1500 patients receive systemic antifungal drugs every year, and annual antifungal purchasing costs increased from US$3.5 million in 2007 to over US$4.4 million in 2009 (26% increase) (data from the Pharmacy Department). In response to the need for more appropriate use of antifungal agents, an AFSP was started in October 2010. By October 2011, the programme was fully implemented. The study was approved by the hospital's institutional review board, the pharmacy and infectious diseases committees, and by the antimicrobial subcommittee.
Steps of the antifungal stewardship programme Our AFSP consisted on two phases: a first-year intervention and a second-year intervention.
First-year intervention. The first-year intervention ran from 1 October 2010 till September 2011, as follows:
(1) We created a multidisciplinary collaborative group on mycosis (COMIC Study group) including all departments involved in IFIs, supported by the hospital administration. This group was responsible for assessing the epidemiology of fungal infections, suggested preventive and therapeutic interventions and proposed standards and local guidelines. Periodic meetings were programmed, and resources were obtained to incorporate an infectious diseases physician, a pharmacist and a data manager with 50% dedication to the programme (approximately 4 h/day). (2) The COMIC study group prepared and distributed local pocketsize clinical guidelines for the diagnosis and treatment of IFIs (October 2010 to March 2011). The guidelines were also approved by the pharmacy committee and by the antimicrobial therapy team. (3) In April 2011, we implemented a non-compulsory Computerized Physician Order Entry system (April 2011), which alerted pharmacists about new antifungal prescriptions and provided real-time alerts to prescribers of potential drug interactions and costs. The programme required justification of the indication according to local guidelines and provided information about the diagnosis and treatment of IFIs and reminders for determination of voriconazole and posaconazole levels. The Computerized Physician Order Entry tool allowed the possibility of prescriptions that did not fulfil local indications. (4) We ran a survey to evaluate physicians' knowledge of the principal prescribing departments involved in the diagnosis and management of IFIs (October 2010 to November 2010). This information was used to design interactive training courses based on clinical cases. A 20-point questionnaire was administered to all participants before and after the course to evaluate the impact and effectiveness of the course [11] . (5) We performed an audit of the use and cost of 100 antifungal prescriptions (December 2010 to January 2011) according to a quality score (scale of 0 to 10) for evaluation of the adequacy of the prescription (Table 1) . The audit enabled us to detect the main problems and to calculate the potential cost-effectiveness of implementing an AFSP [12] . (6) Throughout the first-year intervention period, regular meetings were held with the main prescribing departments to report the interim and final results and to provide and receive feedback.
Second-year intervention. The second-year intervention ran from October 2011 to September 2012. The AFSP team received daily e-mail alerts from the Pharmacy Department on every patient receiving candins, liposomal amphotericin B, voriconazole and posaconazole. (fluconazole, itraconazole and ketoconazole were not considered as targets). All these prescriptions were prospectively audited. The infectious diseases specialists visited the patient and recorded data following a preestablished protocol [12] . Patients receiving any of these antifungal drugs were visited at least when the drug was first administered and when microbiological laboratory results became available. The data collected included demographic information, underlying condition, antifungal prescribed (indication, dose and length of treatment), microbiological results, adjustment of therapy, toxicity and outcome. The patient's progress was always discussed with the attending physician and non-compulsory written diagnostic and therapeutic advice was provided. There was also an intravenous-oral switch programme performed by the AFSP team that suggested the change to an oral antifungal, if possible, and a reminder in the Computerized Prescription Order Entry. After discharge, the outcome of the intervention was evaluated. The AFSP committee had monthly meetings where results, challenges and upcoming ideas were analysed to assess whether the programme was working. The results of the programme were presented to the top prescribing departments and at the COMIC meetings. From September 2012, the AFSP continued to act but data different from cost were not recorded.
Definitions
Antifungal therapy was classified as prophylaxis, empirical, preemptive or targeted.
Prophylaxis. Prophylaxis was defined as treatment prescribed to a patient with risk factors for IFI but no clinical manifestations of the disease.
Empirical therapy. In neutropenic patients, empirical therapy was defined as antifungal drugs administered to treat persistent fever in cases were broad-spectrum antibacterial therapy had not produced positive microbiological results. In non-neutropenic patients, empirical therapy was defined as antifungal therapy initiated to treat suspected IFI with no positive microbiological results.
Pre-emptive therapy. In neutropenic patients, pre-emptive therapy was defined as early treatment for probable IFI based on clinical or radiological data and/or positive biomarkers. In nonneutropenic patients, pre-emptive therapy was defined as antifungal drugs administered to patients with clinical signs, risks factors and a Candida score of more than two points [13] .
Targeted therapy. This was defined as treatment of a microbiologically proven infection.
Candidaemia-related mortality. This was defined as mortality occurring within 1 month after the candidaemia episode.
Appropriateness of antifungal prescription. The criteria used to define the appropriateness of antifungal prescription were based on the guidelines of the Infectious Diseases Society of America, the European Conference on Infections in Leukaemia [14] [15] [16] and on local susceptibility patterns. Adequate dosage recommendations, dose adjustments for hepatic and/or renal Total score (From 0 to 10). a Both low and high doses were considered incorrect. Adjustment for renal and hepatic failure and drug-to-drug interactions were also addressed. At the time of the study, monitoring of serum voriconazole and posaconazole was not available. b Durations that were too short and too long were considered incorrect.
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Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 dysfunction, and drug interactions were also taken into consideration. The adequacy of antifungal use was evaluated using a point score previously defined by three senior infectious diseases specialists and one senior pharmacist during three consensus meetings. This adequacy score has a maximum of ten points and was applied to assign a relative weight to each of the items evaluated based on adequacy, efficiency and safety, as follows: correct indication, optimal selection, correct dosage, correct administration route, correct adjustment according to microbiological results, and adequate length of therapy. The score is detailed in Table 1 and was previously published by our team. Any prescription with a global score other than 10 was judged inappropriate [12] . Antifungal appropriateness was assessed by the senior infectious diseases specialist and the senior pharmacist specializing in mycology in charge of the AFSP. Discordances were resolved by a second senior infectious diseases specialist.
Antifungal toxicity. This was assessed in every intervention by means of physical examination, review of the clinical chart and of the laboratory results. In case of no other feasible justification of the abnormalities, adverse events were classified as potentially related to the antifungal therapy.
Expenditure objectives and cost analysis
The expenditure objective for the AFSP was purposefully conservative: to reduce total antifungal spending by at least 10% annually in the inpatient setting. We used an opportunity sampling (all patients treated during the study period). Given an antifungal consumption of US$3.8 million during the 12 months before implementation, this financial goal would generate a net saving of US$300 000 to US$350 000 per year after considering the cost of additional staff required.
To estimate the effect of the AFSP on antifungal consumption, an interrupted time series analysis (ITS) with monthly AF cost data was performed comparing 36 months preceding the implementation of the program (pre-intervention period) to the 36 months after its implementation. The last 12 months were included in the analysis to investigate the sustainability of the intervention (see Supporting information: Interrupted time series analysis).
Antifungal drug costs were calculated prospectively based on the actual dose administered and the drug acquisition costs for each year. This price may differ from the officially established price, owing to discounts negotiated with antifungal drug suppliers. All costs in euros were converted to US dollars, based on the exchange rate at 30 September 2013 (V1 = US$1.35).
As complementary data, the defined daily doses (DDDs) were also provided by the Pharmacy Department. DDDs were determined according to dosages recommended by the WHO (http://www.whocc.no/atc_ddd_index/). A DDD is the average maintenance dose per day for a drug in its main indication for adults. Because no DDD was suggested for liposomal amphotericin B, we selected 200 mg, which was thought to represent a typical daily dose for an adult with normal renal and hepatic function. DDDs were expressed per 1000 patient-days.
Statistical analysis
Data were entered into a database created using MICROSOFT ACCESS ® . The qualitative variables appear with their frequency distributions. Normally distributed quantitative variables are expressed as the mean and standard deviation (SD); nonnormally distributed variables are expressed as the median and interquartile range. The t-test or analysis of variance was used to compare how scores differ according to department.
An ITS was conducted to detect whether or not the AFSP had a significant effect over the natural evolution of the time series. This analysis permits the detection of changes in level immediately after intervention, of differences between preintervention and post-intervention slope and the estimation of monthly average intervention effect after the intervention.
Finally, trends in rate of candidaemia per 1000 admissions were evaluated using Poisson regression analysis. Proportions were compared using Mantel-Haenstel chi-squared test.
A p value 0.05 was considered statistically significant. STATA/ SE 12.0 (StataCorp LP, 4905 Lakeway DriveCollege Station, Texas, USA) and IBM SPSS STATISTICS 19.0 software (IBM Corporation, 1 New Orchard Road Armonk, New York, USA) were used for the statistical analysis and the interrupted time series analysis.
Results
Demographic and clinical characteristics of patients included in the bed-side approach (second year of intervention) From October 2011 to October 2012, systemic antifungal therapy was prescribed to 1506 patients (30.5/1000 admissions). After excluding 1053 patients who received fluconazole, the population of the second-year bedside intervention comprised 453 patients treated with candins, voriconazole, posaconazole or amphotericin. Patients were initially evaluated an average of 3 days after antifungal prescription.
Invasive fungal infections was demonstrated in 131 patients receiving antifungals (28.9%): 105 (23.2%) were caused by yeasts, 25 (5.5%) by moulds, and one by both (0.2%). Overall, 155 microorganisms were isolated, and three patients were diagnosed using only indirect tests (galactomannan) (see Supporting information, Table S1 ).
Most patients were men (69.3%), and median age was 51 years (see Supporting information, Table S2 ). The main prescribing departments were haematology (34.4%), medical departments (23.2%), and ICUs (19.9%) (Table S2 ). The indications for prescribing antifungals were targeted therapy (36.4%), prophylaxis (32.2%), empirical therapy (19.6%) and pre-emptive therapy (11.7%).
After the final review of the clinical charts, probable antifungal-related toxicity was found in 31 cases (6.8%). Renal toxicity was suspected in nine patients, all of whom received liposomal amphotericin B. Hepatic toxicity was suspected in 18 patients: six were treated with posaconazole, two with caspofungin, two with micafungin, and one with voriconazole. Median hospital stay was 35 days, and in-hospital mortality was 26.9% (9.3% IFI-related) ( Table S2 ).
Use of restricted antifungal drugs
The most common antifungals prescribed were liposomal amphotericin B (25.8%), micafungin (23.4%) and posaconazole (17.0%) (see Supporting information, Table S3 ). A total of 167 patients (36.9%) received more than one drug, 128 (28.3%) received two, 25 (5.5%) received three, and 14 (3.1%) were treated with four different drugs. Median treatment duration was 14 days (interquartile range 7-26).
We observed a relationship between main indication and prescribing department: prophylaxis predominated in the haematology unit (75.6% of prescriptions), pre-emptive treatment in the ICUs (37.8%), and targeted therapy in the medical and paediatric wards (72.4% and 63.9%, respectively).
There was also a clear relationship between drug and indication. Posaconazole (46.6%) and micafungin (34.2%) were the preferred drugs for prophylaxis. Candins were widely used for pre-emptive therapy, accounting for 47/53 treatments with this indication (88.7%). Liposomal amphotericin B was mainly used as targeted therapy (46.7%) and to treat leishmaniasis (31.6%). Micafungin was the second most common antifungal drug used for targeted therapy (17.6%) and for prophylaxis (34.2%).
Diagnostic and therapeutic advice at the initial visit
No diagnostic advice was deemed necessary in 270 patients (59.6%), but 294 recommendations were made in the remaining 183 (40.4%) ( Table 2 ). The most common recommendations included blood or catheter cultures (35.9%), serological determinations and/or antifungal levels (19.7%), and radiological tests (13.9%).
At the initial visit, no change in therapy was deemed necessary in 68.4% of patients. In the remaining patients, the most common recommendation was to de-escalate the antifungal drug (17.4%) or to discontinue it (7.1%).
Adequacy of antifungal therapy: final evaluation
The final evaluation of the clinical charts showed that the mean point score for antifungal use was 8.64 ± 1.81 (Table 2) .
Overall, inadequacy in one or more of the features evaluated was found in 45% of antifungal courses. The most common problems were inadequate length of therapy (28.5%), inadequate choice of antifungal drug (24.1%), and lack of adjustment to microbiology results (18.5%).
Impact on costs and on antifungal consumption
The annual costs before and after implementation of the AFSP are presented in Table 3 . After 1 year of intervention, the annual costs were reduced from US$3,817,455 to US$3,288,292 (13.9% reduction). Subsequently, the implementation of the bedside intervention was able to reduce annual costs to US$2,871,497 (12.7% further reduction versus the previous year). The main antifungals involved in cost reduction were candins and voriconazole (Table 3) . Compared with the baseline year, and after considering the cost of the additional staff required, this financial benefit generated a net saving of US$407,663 during the first year and of US$824,458 in the second year.
Monthly costs from October 2007 to September 2013 were studied in an ITS analysis (see Supporting information). Fig. 1 The comparison of DDDs of antifungals in the preintervention and intervention periods is also shown in Table 3 . During the second year of intervention, the number of DDDs consumed/1000 patient-days fell by 17.5% (from 66.4 to 54.8 DDDs) in comparison to the pre-intervention period. Marked reductions in the prescribed DDDs of fluconazole, itraconazole and ketoconazole were observed, and prescription of voriconazole was also reduced by 20.7%. Prescription of oral voriconazole increased (from 63.2% of total voriconazole DDDs to 81.1%), as did oral itraconazole (from 46.7% to 73.4%). The overall DDDs of candins decreased by 11.6% and the DDDs of posaconazole decreased by 12.4% compared with the pre-intervention period. The only antifungal drug for which prescriptions did not fall was liposomal amphotericin B.
Impact on quality of care outcomes
We performed an analysis of the most important secondary clinical outcomes of our programme as shown on Table 4 . Incidence of candidaemia/1000 admissions decreased from 1.49/1000 admissions in 2010 (pre-intervention period) to 1.44/ 1000 admissions in 2012 and to 1.14/1000 admissions in 2013. The reduction was statistically significant for Candida albicans fungaemia. The same occurred with the percentage of fluconazole resistance in candidaemia isolates (fell from 6.1% in 2010 to 3.6% in 2013). Overall, candidaemia-related mortality diminished from 28.0% in 2010 to 16.4% in 2013.
Discussion
An AFSP performed by experienced infectious diseases physicians, pharmacists and clinical microbiologists based on training, non-compulsory bedside intervention, and daily collaboration with the pharmacy department could optimize the use of antifungal drugs in a large tertiary teaching institution. Such a programme would have a significant impact on costs.
Antibiotic stewardship is commonly recommended by most major scientific societies. It is designed to ensure optimal use of antimicrobials and leads to better clinical results, fewer adverse events, less antibiotic resistance and reduced costs. AFSPs are not as well developed as antibacterial stewardship programmes [1] . Antifungal prescription is difficult because of the type of patient affected, the unspecific clinical presentation, and the poor sensitivity of microbiological tests. Furthermore, the high mortality of IFIs and the evidence that early therapy has an impact on mortality has led to extended use of empirical and pre-emptive therapy.
Although approximately 3% of all patients admitted to our hospital receive a systemic antifungal drug, an IFI could be proven in only 28.9% of cases. In a study performed in 169 French ICUs, 7.5% of patients were treated with an antifungal drug; however, even in this high-risk population, an IFI was demonstrated in only 35% [17] .
In our study, which did not include fluconazole, 45% of the antifungal drugs were prescribed outside the haematology unit and the ICU. In other centres, this proportion is 30-32% [18, 19] . We believe that it is essential to identify the individual needs and problems of each area of the hospital and that medical and surgical departments are particularly amenable to AFSPs. We found that targeted therapy was prescribed mainly in medical and surgical wards, whereas empirical treatment and pre-emptive treatment were exceptional in these units. Similar findings were reported by Bassetti et al., who compared cases of candidaemia detected in internal medicine (133/348) with those occurring in other departments [20] and found that 30-day mortality was higher in patients with candidaemia in internal medicine than in other wards (51.1% versus 38.2%, p < 0.02) and that it was probably related to a high proportion of delayed treatment (only 7% of therapy was initiated in the first 48 h after the first blood culture compared with 25% in other units).
In ICUs, antifungals are mainly used as empiric or preemptive therapy. An echinocandin was used in 88.7% of preemptive courses. As patients commonly have renal or hepatic insufficiency or receive continuous renal replacement therapy, the bedside intervention may facilitate detection of incorrect dosages. Swoboda et al. report their experience in a multidisciplinary ICU in which all members agreed to follow a flowchart for using antifungals. The programme resulted in a 50% reduction in antifungal cost, even though the severity and number of admissions did not change. The reduction was mainly due to reduced consumption of caspofungin and voriconazole [4] . Another successful example of an antifungal bundle in an ICU was published by Guarascio et al., who also demonstrated the potential cost savings of discontinuing empirical therapy and de-escalation from caspofungin to fluconazole [8] . In these departments, efforts should be aimed at improving de-escalation based on microbiological data, avoiding unnecessarily prolonged therapy, and switching to oral therapy when possible. In our experience, the number of antifungal DDDs prescribed by ICUs decreased by 49.8%. Associated costs were also reduced.
In haematology departments, antifungal therapy is mainly prescribed as prophylaxis (75.6% of all antifungal prescriptions). In our institution, haematologists participated in the AFSP and became more aware of the importance of avoiding prolonged prophylaxis and the benefit of evaluating the individual need for antifungals day by day. Another important objective in the haematology department is to guide empirical therapy (which represents 21.2% of all antifungal prescriptions) with more efficacious radiology and microbiology studies (diagnosis-driven approach). A very useful flow-chart was proposed by Aguilar-Guisado et al., who applied a simple diagnostic approach by avoiding the use of antifungal drugs in 62% of febrile neutropenic patients [21] All IFIs (14.1%) occurred in patients who had received empirical antifungal therapy, and the IFI-related mortality rate was 2.8% (2/72). Similar positive results have also been published by other authors [22] . In our experience, the use of antifungal drugs decreased by 24.6% in the bone marrow transplant unit and by 35.4% in general oncologyhaematology wards.
Adequacy of antifungal therapy: final evaluation Antifungal stewardship programmes are expected to optimize prescription of antifungal drugs and to improve the diagnosis of fungal infections and the quality of care. Our study demonstrates that at the first bedside assessment, a diagnostic suggestion was necessary in 40% of the patients and that therapy had to be modified in 30%. Mondain et al. demonstrated that an AFSP based on a complete bundle of measures improved the quality of care in candidaemia and invasive aspergillosis and reduced overall mortality [7] . Similar results were found by Antworth et al., who implemented a comprehensive care bundle for the management of candidaemia in a US hospital. The candidaemia care team obtained a significant improvement in adherence to the three measures in the bundle: appropriate therapy after microbiological results, ophthalmological examination performed, and appropriate duration of therapy [23] . Significative p values are in bold.
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We rarely detected a completely unnecessary antifungal prescription at the first bedside visit (4.4%), because we start empirical therapy in infected patients with risk factors and no established diagnosis. This finding was also reported by Raymond et al., who performed an audit of the use of expensive systemic antifungals and found that therapy was correctly initiated in 92% of cases [24] . However, selection of the antifungal drug was often considered inadequate, and in 24.1% of cases it was non-optimal. Raymond et al. found that 54% of prescriptions were inadequate according to international guidelines [24] . In our experience, the rate of inadequacy in any of the aspects considered (indication, drug, dosage, administration route, adjustments, and duration) was 45% and was judged in terms of our local guidelines based on local epidemiology and resistance rates. We observed that deescalation was a significant issue for AFSPs. In our study, the response of antifungal prescribers to microbiological evidence was not always positive, and no subsequent adjustments were made in 18.5% of cases.
Another goal of an AFSP is to minimize complications by optimizing the dose and duration of therapy. Inadequate dosage was recorded in 3.8% of cases and probable antifungal-related toxicity in 6.8%. Patients could benefit from a bedside intervention that identifies antifungal-related toxicity and potential medication interactions and suggests therapeutic drug monitoring. Ananda-Rajah et al. also concludes that toxicities of antifungal agents are part of the rationale for AFSPs [1] .
Finally, another important objective of our intervention was to reduce unnecessarily prolonged therapy: length of therapy was inadequate in 28.5% of patients.
Economic impact and potential cost savings
Our non-compulsory programme made it possible to reduce antifungal expenditure without complications in patients whose drugs were switched or discontinued. The main component of the cost savings was the reduction in the use of candins in haematology (from 101 to 62 DDD/1000 patient-days) and in the ICUs (from 88 to 76 DDD/1000 patient-days). Compared with the pre-intervention period, total antifungal expenditure was reduced by 32% (-US$208,048) and 33% (-US$384,346) during the second year of intervention, respectively. These savings resulted from more restricted use of prophylaxis in patients receiving remission-induction chemotherapy for acute myeloid leukaemia or myelodysplastic syndromes and empirical treatment in critical patients with a low percentage of infections by fluconazole-resistant Candida. The AFSP also led to a significant reduction in the prescription of voriconazole and increased use of the oral formulation (low cost and excellent bioavailability). Interestingly, our educational and bed-side intervention also led to a reduced use of non-targeted drugs such as fluconazole.
It is difficult to compare our data with those from other hospitals because the literature contains few studies on antifungal stewardship. After implementation of the AFSP, total antifungal use in our hospital was 55 DDDs per 1000 patientdays, which is lower than the post-intervention 100-120 DDDs per 1000 patient-days reported elsewhere [5, 25] . Apisarnthanarak et al. reported 117 DDDs per 1000 patient-days for fluconazole only [3] , and López-Medrano et al. reported 296 DDDs per 1000 patient-days for voriconazole, caspofungin and liposomal amphotericin B [6] . Only the study of Mondain et al. [7] demonstrated lower consumption of antifungals during a 6-year AFSP (always <40 DDD per 1000 patient-days with a cost of <US$2 million).
Although our programme failed to reduce the use of liposomal amphotericin B, it is important to remember that this is the drug of choice for leishmaniasis, which is a common parasitic disease in Spain. In fact, 31.6% of prescriptions of liposomal amphotericin B were for leishmaniasis. In the other existing study of AFSP in Spain, use of amphotericin B was also unaffected by the programme (increase of 13.9%) [6] .
Regarding secondary outcomes, our programme helped to reduce candidaemia-related mortality, candidaemia incidence and fluconazole resistance.
Our study is subject to a series of limitations. First, drug prices may differ from the officially established price, owing to discounts negotiated with drug suppliers. As drug prices can vary throughout the study, we cannot rule out a small impact on our results. Second, although the purchase price and drug mark-ups were included in our cost estimates, we acknowledge an underestimation of costs due to the exclusion of administration costs. Third, we could not target fluconazole due to staff limitation, although its use was also reduced during the intervention. Finally, ours is a single-centre study, although we believe that our results may be extensible to similar teaching, tertiary institutions.
In conclusion, a collaborative and non-compulsory stewardship programme based on bedside intervention is an efficacious and cost-effective approach for optimizing the use of antifungal drugs in tertiary teaching institutions.
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